Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUTENSEN-R vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension (FDA-approved indication for the combination product)
Hypertension
One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal half-life: cryptenamine 9-10 h, methylothiazide 18-24 h, reserpine 50-100 h (prolonged due to enterohepatic recirculation and tissue binding; accumulation occurs with daily dosing)
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Reserpine is extensively metabolized in the liver via CYP450 enzymes; chlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 59% (cryptenamine), 50% (methylothiazide), 7% (reserpine); Biliary/fecal: 21% (cryptenamine), 48% (methylothiazide), 90% (reserpine)
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Methylothiazide: 65-70% bound to albumin; Reserpine: 95% bound to alpha-1-acid glycoprotein and albumin; Cryptenamine: insufficient data
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Methylothiazide: 0.25-0.3 L/kg (primarily extracellular fluid); Reserpine: 2.5-7 L/kg (extensive tissue binding, especially adipose and brain); Cryptenamine: ~1 L/kg (moderate distribution)
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: methylothiazide 90-100%; reserpine 50-60% (first-pass metabolism); cryptenamine 40-60% (variable first-pass)
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
e GFR 30-50 m L/min: reduce dose by 50%; e GFR <30 m L/min: contraindicated.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh class A: no adjustment; class B or C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended for use in children.
Not established; avoid use in children.
Initiate therapy at half the standard adult dose (one-half tablet daily) and titrate cautiously due to increased sensitivity to adverse effects.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Reserpine component: Risk of mental depression, which may be severe and can lead to suicide. Use with caution in patients with history of depression.
None
Monitor for signs of depression; discontinue if depression occurs.,Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia) with chlorothiazide.,Orthostatic hypotension with reserpine.,Use cautiously in patients with peptic ulcer disease, renal impairment, or hepatic impairment.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Active peptic ulcer,Ulcerative colitis,History of mental depression,Electroshock therapy,Anuria,Hypersensitivity to reserpine, chlorothiazide, or sulfonamide-derived drugs
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-sodium foods to enhance antihypertensive effect. Grapefruit juice may increase hydralazine absorption; limit intake. Alcohol can exacerbate orthostatic hypotension. Maintain adequate potassium intake (bananas, oranges) unless otherwise instructed.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Use of reserpine component may be associated with increased risk of congenital malformations, but data are limited. Second and third trimesters: Reserpine can cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion; hydrochlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, electrolyte imbalances, and volume depletion. Overall, this combination is classified as pregnancy category C (reserpine) and B (hydrochlorothiazide); avoid use in pregnancy unless benefit outweighs risk.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Reserpine is excreted into breast milk and may cause adverse effects in nursing infants (e.g., nasal congestion, respiratory depression, bradycardia). Hydrochlorothiazide is excreted in small amounts; M/P ratio is approximately 0.6. However, thiazides may suppress lactation. Safety not established; use during breastfeeding is not recommended.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Pregnancy may alter pharmacokinetics of both components; volume expansion may reduce hydrochlorothiazide efficacy. Dose adjustments should be individualized based on blood pressure response and electrolyte monitoring. Generally, use lowest effective dose; avoid in severe hypertension or preeclampsia where oral therapy is inadequate.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
DIUTENSEN-R is a fixed-dose combination of reserpine, hydralazine, and hydrochlorothiazide. Monitor for orthostatic hypotension, especially at initiation. Reserpine may cause nasal congestion and depression; avoid in patients with history of depression. Hydralazine can induce lupus-like syndrome; obtain ANA titers if symptoms develop. Hydrochlorothiazide may cause electrolyte disturbances; check serum potassium and magnesium periodically.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not stop abruptly.,Rise slowly from sitting or lying to prevent dizziness.,Report any signs of depression, unusual bruising, or joint pain.,Avoid excessive sunlight; use sunscreen.,Do not take over-the-counter cold medications without consulting your doctor.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUTENSEN-R vs ALDORIL 25, answered by our medical review team.
DIUTENSEN-R is a Antihypertensive Combination that works by DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUTENSEN-R and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUTENSEN-R is: One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUTENSEN-R and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUTENSEN-R is classified as Category C. First trimester: Use of reserpine component may be associated with increased risk of congenital malformations, but data are limited. Second and third trimesters: Reserpine can caus. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.